Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial
Objective To evaluate the effect of colchicine and high-intensity rosuvastatin in addition to standard of care on the progression of COVID-19 disease in hospitalised patients.Design A pragmatic, open-label, multicentre, randomised controlled trial conducted from October 2020 to September 2021. Follo...
Main Authors: | Jing Lu, Christopher Song, Prashant Patel, Christopher Howes, Michael Cleman, Alexandra Lansky, Tayyab Shah, Marianne McCarthy, Irem Nasir, Herb Archer, Elio Ragheb, Jonathan Kluger, Nitu Kashyap, Carlos Paredes, Prakash Kandel, Mustafa Khan, Haocheng Huang, Faheem Ul Haq, Rami Ahmad, Brian Cambi, Gilead Lancaster, Charles Dela Cruz, Helen Parise |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-02-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/13/2/e067910.full |
Similar Items
-
Impact of colchicine on mortality in patients with COVID-19: A meta-analysis
by: Dimitrios A. Vrachatis, et al.
Published: (2021-09-01) -
Repurposing colchicine’s journey in view of drug-to-drug interactions. A review
by: Dimitrios A. Vrachatis, et al.
Published: (2021-01-01) -
Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial
by: H.G. Gaitán-Duarte, MD MSc., et al.
Published: (2022-01-01) -
Colchicine for pericarditis.
by: Alabed, S, et al.
Published: (2014) -
Colchicine for gout
by: M. S. Eliseev, et al.
Published: (2021-08-01)